Bexagliflozin Drug/Drug Interaction Study With Digoxin
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Bexagliflozin on the Pharmacokinetics of Digoxin in Healthy Subjects
Sponsor: Theracos
Listed as NCT03197324, this PHASE1 trial focuses on Type2 Diabetes Mellitus and remains completed. Sponsored by Theracos, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jul 2019 — Oct 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
-
Jul 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Theracos
For direct contact, visit the study record on ClinicalTrials.gov .